The global neoantigen targeted market is expected to reach USD 3 million by 2030 and anticipated to grow at a CAGR of 55% during the forecast period 2019-2030

Cancer poses a substantial global health challenge, accounting for 0.6 million deaths in the United States alone in 2018 and ranking as a leading cause of mortality worldwide. Projections from the World Health Organization suggest a staggering 70% increase in new cancer cases over the next two decades. While conventional treatments such as chemotherapy, surgery, and radiation therapy are prevalent, their effectiveness in advanced cancer stages remains notably limited. Furthermore, these therapies, due to their indiscriminate and highly toxic nature, significantly compromise patients’ quality of life.

Among various targeted anti-cancer therapies, immunotherapy has emerged as a promising approach. It demonstrates the potential to eliminate tumor cells while minimizing adverse effects. Notably, immune checkpoint inhibitors like PD-1/PD-L1 and CTLA-4 inhibitors have provided lasting clinical benefits to individuals with metastatic tumors. However, these therapies show significant variability in eliciting immune responses among patients, resulting in only a fraction experiencing substantial benefits. Statistics indicate that nearly 70% of individuals treated with single-agent immune checkpoint therapy do not respond effectively.

Advancements in genomic analysis and bioinformatics have enabled more personalized treatment approaches, particularly in the realm of neoantigen-targeted therapies. Cancer neoantigens, representing antigens encoded by tumor-specific mutated genes previously unrecognized by the host’s immune system, offer promising biological targets to enhance the therapeutic efficacy of various cancer immunotherapies. These neoantigens have demonstrated the capacity to stimulate robust T-cell mediated immune responses, holding immense potential in augmenting immune checkpoint inhibitors and cancer vaccines. Currently, several investigational neoantigen-based therapies are under scrutiny alongside diverse immune checkpoint inhibitors such as atezolizumab, durvalumab, ipilimumab, and nivolumab. Numerous initiatives led by start-ups, supported by venture capital firms and strategic investors, are dedicated to exploring and advancing these therapeutic avenues.

Report Coverage
? The report examines the neoantigen targeted therapies market across multiple parameters, including target indications, treatment types, immunotherapy forms, administration routes, and geographical regions.
? It thoroughly analyzes the factors influencing market growth?such as drivers, restraints, opportunities, and challenges.
? Evaluates the potential benefits and barriers within the market, providing insights into the competitive landscape for major market players.
? Projects revenue forecasts for market segments across various countries.
? Conducts a comprehensive assessment of the current cancer treatment market, including categorization based on development phases, molecule types, treatment approaches, therapy types, immunotherapy specifics, target indications, treatment lines, and drug administration methods.
? Offers detailed profiles of leading developers of neoantigen targeted therapies, focusing on their robust pipeline products, encompassing company overview, financial insights (if available), product portfolio, recent collaborations, and future projections.
? Analyzes around 300 scientific articles published between 2015 and early 2019, highlighting research trends in disease indications, associated cancer immunotherapies, publication types, years, and influential journals contributing to the neoantigen targeted therapies market during that timeframe.
? Conducts an in-depth examination of patents related to neoantigens up to April 2019, covering patent types, publication years, issuing authorities, assigned CPC symbols, emerging focuses, and major industry/academic entities with significant intellectual property portfolios in this field.
? Analyzes partnerships related to neoantigen targeting therapies established until March 2019, categorizing them by partnership types, years, targeted disease indications, immunotherapy modalities, and the most active entities involved in these collaborations.
? Assesses investments in companies focused on developing neoantigen targeted therapies, encompassing various financing forms such as seed financing, venture capital, debt financing, grants, initial public offerings (IPOs), and subsequent offerings at different developmental stages.


Key Market Companies
? Bavarian Nordic
? Genocea Biosciences
? Gradalis
? Immunicum
? Immunovative Therapies
? Iovance Biotherapeutics
? MediGene
? Neon Therapeutics